

**VTAMA CREAM
(tapinarof)****RATIONALE FOR INCLUSION IN PA PROGRAM****Background**

Vtama (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. Vtama is used in patients with plaque psoriasis or atopic dermatitis. The specific mechanism by which Vtama cream exerts its therapeutic action is unknown (1).

Regulatory Status

FDA-approved indication: Vtama cream is an aryl hydrocarbon receptor agonist indicated for: (1)

- the topical treatment of plaque psoriasis in adults.
- the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

The safety and effectiveness of Vtama cream in pediatric patients less than 18 years of age with plaque psoriasis have not been established. The safety and effectiveness of Vtama cream in pediatric patients less than 2 years of age with atopic dermatitis have not been established (1).

Summary

Vtama (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. Vtama is indicated for use in patients with plaque psoriasis or atopic dermatitis (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Vtama while maintaining optimal therapeutic outcomes.

References

1. Vtama [package insert]. Long Beach, CA: Dermavant Sciences Inc.; December 2024.